GACL FY26 PAT rises 32% to ₹208 crore, recommends dividend
Gujarat Alkalies and Chemicals reported a 32% rise in FY26 PAT to ₹208 crore, driven by a 7% revenue increase to ₹4,358 crore. The Board recommended a final dividend of ₹17.70 per share. While standalone results improved, consolidated figures showed a net loss of ₹241 crore, narrowed from the previous year, due to losses in its joint venture. The company approved a ₹67 crore investment in a new hydrogen peroxide plant and other strategic initiatives.

*this image is generated using AI for illustrative purposes only.
Gujarat Alkalies and Chemicals reported a 32% increase in profit after tax (PAT) to ₹208 crore for the financial year ended March 31, 2026, compared to ₹158 crore in the previous year. Revenue from operations rose 7% to ₹4,358 crore from ₹4,073 crore in FY25. The Board of Directors approved the audited financial results for the fourth quarter and full year at meetings held on May 28 and May 29, 2026, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance and Dividend
The Board recommended a final dividend of ₹17.70 per equity share, or 177%, for the year ended March 31, 2026. The total dividend outgo amounts to ₹1,299.83 crore on 7,34,36,928 equity shares of ₹10 each. The statutory auditors audited the financial results, which were reviewed by the Audit Committee. The company's EBITDA for the year increased by 15% to ₹522 crore, driven by higher capacity utilization and improved sales realizations.
Consolidated Results and Joint Venture
The consolidated financial results for FY26 reported a net loss of ₹241 crore, compared to a net loss of ₹651 crore in the previous year. The consolidated figures include the results of joint venture company GACL-NALCO Alkalies & Chemicals Pvt. Ltd. (60%) and 26% of associates. The joint venture incurred losses of ₹386.87 crore during the year, with accumulated losses of ₹6,333.08 crore as of March 31, 2026. An external expert assessment determined that no impairment provision is required against the company's investment of ₹4,140 crore in the joint venture, as the fair value exceeds the carrying amount.
Capital Expenditure and Strategic Initiatives
The Board approved the establishment of a 5000 TPA High Purity Grade Hydrogen Peroxide Plant at Dahej, Gujarat, with an estimated investment of ₹67 crore. The project is scheduled to be commissioned in 18 months and is expected to contribute approximately ₹42 crore to annual sales revenue. The facility aims to serve niche applications in semiconductor fabrication, solar cell manufacturing, and advanced electronics. Funding will be sourced from internal accruals, with need-based gaps met through borrowings.
| Financial Metric | FY26 (₹ in Lakhs) | FY25 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 4,35,808 | 4,07,291 |
| Profit for the Period | 2,084 | 1,582 |
| Total Income | 4,47,470 | 4,16,505 |
| Earnings Per Share (Basic) | 2.84 | 2.15 |
The Board also approved the remembrancing and recoating of generation VB+ Cell elements at the Vadodara Complex to reduce power costs and the implementation of a digitization and AI strategy, including migration to SAP S/4HANA. For the current financial year, the company expects to commission several projects, including an HCl Synthesis Unit and 138.60 MW of renewable energy projects.
Historical Stock Returns for Gujarat Alkalies & Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.79% | -3.19% | -16.92% | +27.12% | +14.39% | +63.48% |
What strategies will GACL implement to turn around the joint venture's performance given its substantial accumulated losses?
How will the commissioning of 138.60 MW of renewable energy projects impact the company's power costs and EBITDA margins in the coming year?
Will the company pursue further expansion into high-purity chemicals for the semiconductor sector following the new Hydrogen Peroxide plant investment?


































